A pioneering drug trial has been initiated by scientists to potentially aid pets lose weight.
Okava Pharmaceuticals, a US-based company, is commencing a trial named MEOW-1 (‘ManagEment of Over Weight cats’), marking the first weight loss study for domestic pets. Around 50 cats are set to receive the implant and undergo weight assessments after three months within the research. If effective, the plan is to extend the study to include dogs.
The novel drug, OKV-119, leverages a specialized version of GLP-1 receptor agonists tailored for pets, akin to those present in popular human weight loss medications like Wegovy and Mounjaro.
Describing its mechanism, Michael Klotsman, CEO of Okava, explained: “Caloric restriction, or fasting, is a well-established method for enhancing lifespan and metabolic health in cats. However, it is challenging to sustain. OKV-119 is devised to simulate numerous physiological benefits of fasting, such as enhanced insulin sensitivity, reduced fat mass, and more efficient energy metabolism, without necessitating significant alterations in feeding habits or disrupting the human-animal bond often centered around food.”
A spokesperson from Okava highlighted the drug’s potential to improve the quality of life, foster healthy aging, and potentially become the most impactful longevity-promoting therapy for cats. Envisaging a monthly cost below $100 (£75), the company aims to offer the treatment at a lower price point than the £125 Wegovy private prescription cost in the UK.
Early studies endorsed by the company indicate the safety and benefits of the implant and GLP-1 treatment for pets. Okava asserts that the medication functions similarly in pets as in humans, suggesting that pet owners can anticipate significant behavioral changes in their animals.
“Notably, pets are expected to exhibit reduced food-driven behaviors – displaying less begging, decreased scavenging, and improved portion control. Apart from changes in appetite, owners may notice more active and energetic pets as weight diminishes and metabolic health enhances.”
The MEOW-1 trial will be overseen by the US Food and